Chimeric Peptide Disrupts PSD-95 Binding for Stroke Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for stroke fail to effectively reduce brain damage by directly protecting neurons from death, with existing NMDA receptor antagonists causing severe side effects due to binding with N-type calcium channels.
Innovation Solution
Development of a chimeric peptide that inhibits the binding of PSD-95 to NMDA receptors and promotes cellular uptake, reducing binding to N-type calcium channels, thereby minimizing side effects while maintaining neuroprotective efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMDA receptor antagonists are used to treat stroke, then neuroprotective efficacy is improved, but severe side effects occur due to binding with N-type calcium channels
Solution Approach 1:
The invention segments the therapeutic action by using a chimeric peptide that specifically targets the PSD-95/NMDA receptor interaction site, separating the neuroprotective function from the harmful N-type calcium channel binding function. The peptide is designed to inhibit PSD-95 binding to NMDA receptors while having reduced affinity for N-type calcium channels, thus achieving selective neuroprotection without severe side effects.
Solution Approach 2:
The chimeric peptide acts as an intermediary that disrupts the pathological coupling between PSD-95 and NMDA receptors during ischemic excitotoxicity. By interfering with this specific protein-protein interaction, the peptide mediates neuroprotection without requiring broad-spectrum NMDA receptor antagonism that would block N-type calcium channels and cause side effects.
2Reliability
If non-selective NMDA receptor antagonists are used, then neuroprotection is enhanced, but therapeutic selectivity is reduced leading to broader side effects
Solution Approach 1:
The chimeric peptide exhibits local quality by being specifically designed to target the PSD-95 binding site on NMDA receptors, which is critically involved in ischemic excitotoxicity. This localized targeting provides high therapeutic selectivity for stroke pathology while sparing other physiological functions mediated by NMDA receptors in different contexts.
Solution Approach 2:
The invention changes the binding parameters of the therapeutic agent by modifying the peptide sequence to reduce affinity for N-type calcium channels while maintaining or enhancing affinity for the PSD-95/NMDA receptor interface. This parameter optimization achieves selective neuroprotection with an improved therapeutic window.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric peptide effectively reduces brain damage in stroke models by disrupting neurotoxic signaling during ischemia without the severe side effects associated with N-type calcium channel binding, enhancing the therapeutic index for stroke treatment.
Implementation Method 1
the chimeric peptide comprises an active peptide that inhibits binding of PSD-95 to an NMDA receptor
Implementation Method 2
an internalization peptide that promotes uptake of the chimeric peptide into cells
Data Source
AI summary
The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.